
    
      This is a randomized, double-blind study of MSDC-0602K or placebo given orally once daily to
      subjects with pre-T2D or T2D and evidence of NAFLD/NASH. Visits will include a Screening
      Period, a minimum Treatment of 26 weeks, and a Long-Term Follow-up Period during which
      subjects will continue taking assigned treatment.

      Safety will be assessed by periodic measurement of vital signs, physical examinations, blood
      laboratory analyses, and the occurrence of adverse events.
    
  